Palbociclib shows promising results in patients with hormone receptor-positive metastatic breast cancer
The drug palbociclib, an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, significantly improved progression-free survival when administered as a first-line treatment in patients with hormone receptor-positive, metastatic ...
Apr 7, 2014
0
0